Physician profile
Brian Cameron Galbraith
NPI 1699976241
$1,767.51
in general payments reported to CMS, 2019-2025
6 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $117 · 2020: $849 · 2021: $518 · 2022: $147 · 2023: $136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $136.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Align Technology, INC. | $917.70 | 2020-2023 | Itero Element, Invisalign First - Comprehensive |
| A-Dec, INC. | $655.00 | 2020 | |
| Biolase, INC. | $91.09 | 2019-2022 | |
| Salvin Dental Specialties, INC. | $78.51 | 2019 | |
| Dentsply Sirona INC | $14.04 | 2020 | |
| 3m Company | $11.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Galbraith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.